Navigation Links
Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
Date:1/16/2008

Cheryle R. Hart, M.D. Clarifies Previous Statement on 1/11/08

SPOKANE, Wash., Jan. 16 /PRNewswire/ -- On January 9, 2008 the FDA raised the issue regarding the use of estriol in compounded hormone replacement therapy. While awaiting further clarification, Dr. Hart suspended prescribing estriol in her medical practice. Cheryle Hart, M.D. is Mayo Clinic trained and Board certified in Ob/Gyn and founded what is now Hormones by Hart in 1997. She is also the medical director of Hormones by Hart.

Dr. Hart has been discussing this issue with medical experts in hormone replacement therapy and with some of the most experienced compounding pharmacies across the U.S. "I have learned that compounded hormone prescriptions containing estriol have been and continue to be prescribed as an important part of Hormone Replacement Therapy (HRT) throughout the United States," says Dr. Hart. The continuation of such compounding remains the subject of a major dispute between compounding pharmacies and the FDA.

The International Academy of Compounding Pharmacists (IACP) -- who represents thousands of compounding pharmacies -- says that the situation with estriol is comparable to many commonly prescribed drugs. While estriol was never formally approved by the FDA, it has a monograph from the U.S. Pharmacopeia (USP) prior to 1997. When Congress passed the FDA Modernization Act in 1997, Congress clearly indicated that drugs with a USP monograph could still be compounded when prescribed by a licensed medical practitioner.

"With this new information and clarification from the IACP, I am updating my previous intentions about prescribing compounds containing estriol," says Dr. Hart. "Until the courts give us the final word on this subject, I will continue to prescribe estriol as an important part of the total hormone replacement therapy for my patients -- whom I have found to benefit from its use. I want my patients to know that all of their prescription hormones are still going to be available," promises Cheryle R. Hart, M.D.

If you would like to let the FDA know how you feel, please go to their comment website at: http://www.fda.gov/cder/comment.htm

IACP Reply to FDA News on BHRT: http://www.iacprx.org/

Statement From The American Pharmacists Association Regarding FDA's Action http://www.medicalnewstoday.com/articles/93953.php

Original FDA News Release January 9, 2008: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01772.html


'/>"/>
SOURCE Cheryle R. Hart, M.D.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
7. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
10. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
11. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia is ... complete. The new structure adds a third office building to the current facilities. ... 2.4 acres of land, along with office space adjacent to the previous main building. ...
(Date:5/19/2016)... 2016 Regen BioPharma, ... RGBPP) announced today initiation of a preclinical development ... based cancer immunotherapeutic product leveraging its NR2F6 immunological ... a generation of cord blood derived killer cells ...  The product in development will be a "universal ...
(Date:5/18/2016)... 18, 2016 The Biotech industry continues ... mean that there are no opportunities ahead. Today, ActiveWallSt.com has ... THLD ), Seattle Genetics Inc. (NASDAQ: ... Ophthotech Corp. (NASDAQ: OPHT ). Sign up now ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):